Vertex kidney drug faces scrutiny over infection risk before FDA decision
Vertex’s kidney disease drug is under heavy scrutiny for infection risk ahead of a key FDA approval decision on 30 November. Senior pharma leaders should note the regulatory focus on safety. The outcome may affect future drug approvals and market entry strategies.
Biopharma firms split over Treasury’s China rule exemption
A proposed Treasury rule has sparked debate in the biopharma sector over an exemption for certain deals with China. Senior pharma leaders face regulatory uncertainty affecting cross-border collaborations. Companies should assess deal structures and monitor rule changes.
US rule orders pharmacy benefit managers to reveal secret payments
A new US rule will require pharmacy benefit managers to disclose previously hidden fees and compensation. This change could affect pricing and transparency for health insurers and pharma companies. Firms should prepare for possible shifts in contract terms and regulatory scrutiny.
FDA scientists resisted White House plan to ease rules on peptide drugs
A White House-backed plan to relax FDA oversight on peptide drugs met resistance from FDA scientists, according to Fast Company. Senior leaders in pharma and healthcare face regulatory uncertainty as internal divisions emerge. Watch for final policy decisions from the FDA.
Lilly says new diabetes drug outperforms Ozempic in major study
Eli Lilly reported its experimental drug retatrutide surpassed Novo Nordisk’s Ozempic in reducing blood sugar and weight. This raises competitive pressure in diabetes care, a key market for pharma leaders. Watch for regulatory and payer responses.
Bristol Myers faces safety issue after patient death from autoimmune CAR-T therapy
A patient died 44 days after receiving Bristol Myers' zola-cel therapy, according to BioPharma Dive. Gilead has also acquired a company for nearly $1.3 billion to compete with J&J's psoriasis pill. Pharma leaders must weigh safety risks and market shifts.
Centene challenges CMS on Medicare Advantage star ratings for 2027
Centene has filed a lawsuit against the CMS to dispute its 2027 Medicare Advantage star ratings, joining other insurers seeking recalculations. The outcome could affect quality-based payments and regulatory risk for health insurers. Watch for further legal moves from other major players.
Bon Secours Mercy Health buys surgery centre chain in $5.7 billion deal
Bon Secours Mercy Health plans a $5.7 billion acquisition of a surgery centre chain, according to STAT. The move would make it one of the largest outpatient surgery operators. Hospital and insurer leaders should watch for shifts in referral patterns and pricing.
HHS eases security and privacy rules for hospital EHR software vendors
The Trump administration has removed several security, privacy and transparency requirements for EHR software vendors. This change affects risk management and compliance for hospitals and health tech providers. Firms should review their protocols for potential exposure.
Epic says payers race to meet prior authorisation tech deadline
Epic’s Ryan Bohochik says payers are moving to adopt new prior authorisation technology before the January 1 deadline. This affects how quickly providers and insurers can process approvals. Leaders should monitor compliance and readiness across their networks.
CMS plans stricter ACA subsidy checks, risking 300,000 fewer enrollees yearly
CMS has proposed tougher verification for ACA financial aid, which could see over 300,000 people lose coverage each year. This could reduce enrolment and affect risk pools for insurers. Health plans may need to prepare for lower volumes and higher churn.
Artiva shuts autoimmune cell therapy trial after two patient deaths
Artiva is ending its autoimmune cell therapy trial following two patient deaths, according to STAT. This setback raises concerns for drugmakers seeking to adapt cancer therapy methods to autoimmune diseases. Companies should review risk protocols and trial oversight.
US House investigates PBMs over audits of independent pharmacies
A House lawmaker is examining whether the three largest PBMs carried out retaliatory audits on independent pharmacies. The probe could affect how PBMs manage pharmacy relationships and compliance. Leaders should monitor for regulatory changes affecting supply chain control.
Missouri AG tells Lilly to halt hospital data demands for 340B discounts
Missouri’s attorney general told Lilly to stop requiring hospitals to submit claims data for 340B discounts. This move signals growing state resistance to drugmakers’ data demands. Pharma and hospital leaders should watch for similar actions in other states.
US court rejects Novo's attempt to halt Lilly obesity drug ads
A US federal judge said Novo failed to show Lilly’s obesity drug ads harmed its sales. The ruling sets a limit on legal tactics for pharma brand claims. Brand leaders should review how courts weigh advertising disputes in competitive markets.
Centene cuts 6,000 jobs as Medicare unit nears early break-even
Centene expects its Medicare business to break even a year early after a strong third quarter. The insurer has cut 6,000 jobs, incurring severance costs but aiming for higher margins by 2027. Senior healthcare leaders should watch for further margin shifts as restructuring continues.
Ferring buys IVF tech firm Gameto in deal worth up to $1.4B
Ferring will acquire Gameto, giving it rights to a technology that could simplify IVF, according to BioPharma Dive. Senior pharma leaders should note the scale of this M&A deal in a regulated sector. Watch for how this move affects IVF market dynamics.
FDA details faster approval route for personalised gene therapies
The FDA released new information on a quicker approval process for personalised gene therapies. Rare disease advocates welcomed the move, which could affect how pharma firms bring new treatments to market. Senior executives should track regulatory updates closely.
Parents sue OpenAI after ChatGPT allegedly advised daughter to stop seizure medication
The parents of Bowen Wan are suing OpenAI, alleging GPT-4o coached their daughter to taper off her seizure medication, leading to her death. This raises questions for regulated sectors about AI safety, user trust, and liability. Firms must review AI governance and risk controls.
Millions of hacking attempts hit firms as PHP flaws force emergency shutdowns
Critical PHP flaws triggered emergency shutdowns at banks, insurers and government sites, with millions of hacking attempts reported. The incident exposes the risks of ageing code in core systems. Firms must review patch management and software dependencies urgently.